Hypothetical In-vivo Behavior of Pediatric Dosage Forms: Ibuprofen Oral Suspensions Hypothetical in-vivo behavior of ibuprofen suspensions
Iranian Journal of Pharmaceutical Sciences,
Vol. 21 No. 1 (2025),
21 January 2025
,
Page 461-469
https://doi.org/10.22037/ijps.v21i1.47326
Abstract
The hypothetical plasma concentration-time profiles of ibuprofen pediatric formulations using in-vitro release data of the mini-paddle apparatus and the USP apparatus were proposed. Dissolution conditions were as follows: a mini-paddle apparatus at 75 rpm, 200 mL of medium, a USP apparatus 4 laminar flow at 16 mL/min, and phosphate buffer (pH 6.8). Five commercial formulations (reference and four multi-source drug products) were used. Samples were taken at previously established times for up to 60 minutes. The dissolved drug was quantified by UV derivative spectrophotometric analysis. Profiles were compared with different approaches, and dissolution data were fitted with several mathematical equations. Predicted in vivo behavior was calculated using dissolution data from both apparatuses and published pharmacokinetic information through a convolution approach. Validation of the results was carried out by calculating the prediction error (PE) for the hypothetical peak plasma level (Cmax) as well as the area under the curve from zero to infinity (AUC0-inf). Calculations are valid if PE is equal to or less than 10%. Considering the f2 value, similar in-vitro release curves of all suspensions were found using data from the USP apparatus 4 (f2 > 50). No statistically significant differences were calculated for the release parameters of B and C drug products, respectively, using data from the USP apparatus 4. PE < 10% for Cmax and AUC0-inf in the same formulation was only found with R, B, and C drug products, based on data from the USP apparatus 4. This apparatus appears to be the appropriate choice for assessing the biopharmaceutical quality of pediatric ibuprofen formulations.
- Convolution
- Ibuprofen
- Inverse Release Function
- Prediction Error
- Suspension
- USP apparatus 4
How to Cite
References
1. WHO Model List of Essential Medicines – 23rd List (2023). http://chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://iris.who.int/server/api/core/bitstreams/289a875c-cc89-4914-90ad-eb3c578ebaf6/content (Accessed Oct 5, 2025).
2. Potthast et al. Biowaiver monographs for immediate release solid oral dosage forms: ibuprofen. J. Pharm. Sci. (2005) 94 (10): 2121‒2131.
3. United States Pharmacopeia and national formulary USP43-NF38; The United States pharmacopeial convention. Rockville, MD: Inc; 2021.
4. Medina-López JR, Pacheco JG, Rojas PA, Castro N. Derivatives of the ratio spectra for determination of acetylsalicylic acid, acetaminophen, and caffeine in fixed-dose combination formulations: application to dissolution studies. Int. J. App. Pharm. (2020) 12 (6): 253‒257.
5. Klein S, Shah VP. A standardized mini paddle apparatus as an alternative to the standard paddle. AAPS PharmSciTech. (2008) 9 (4): 1179‒1184.
6. Mohammadi A, Moghaddas JS. Experimental and computational study on hydrodynamic of a downscaled mini vessel USP dissolution test apparatus II. Iranian J. Chem. Engineering. (2019) 16 (3): 3‒22.
7. Abdelfattah F, Taha N, Abdou A, Mursi N and Emara L. Prediction of in-vivo performance of ibuprofen immediate-release products using different dissolution models. J. App. Pharm. Sci. (2022) 12 (8): 193‒201.
8. Medina-López JR, Ríos-López A, Reyes-Ramírez FD. Convolution approach to estimate the in-vivo behavior of ibuprofen soft gelatin capsules from in vitro release data of USP Apparatus 4. Int. J. Res. Pharm. Sci. (2024) 15 (4): 88‒94.
9. Medina-López JR, Soto-Juha JA, Contreras-Jiménez JM. Rapid and simple determination of ibuprofen and caffeine in fixed-dose combination formulations: application to dissolution studies. Int. J. Appl. Pharm. (2021) 13 (3): 242‒246.
10. Zhang Y, Huo M, Zhou J, Zou A, Li W, Yao C, Xie S. DDSolver: an add-in program for modeling and comparison of drug dissolution profiles. AAPS J. (2010) 12 (3): 263‒271.
11. Cardot JM, Lukas JC, Muniz P. Time scaling for in vitro-in-vivo correlation: the inverse release function (IRF) approach. AAPS J. (2018) 20 (6): 95.
12. Qureshi SA. In vitro–in-vivo correlation (IVIVC) and determining drug concentrations in blood from dissolution testing – a simple and practical approach. Open Drug Deliv. J. (2010) 4: 38‒47.
13. Poveda Andrés JL, García Robles AA, Pérez Huertas P. Farmacología del ibuprofeno intravenoso. Rev. Soc. Esp. Dolor (2016) 23 (Supl. I): 3‒12.
14. Villalva-Rojas O, Grande-Ortíz M, Ortiz J, Isasi J, Yantas D, Fiestas V. Estudio de bioequivalencia del ibuprofeno 400 mg tabletas. Rev. Peru. Med. Exp. Salud Publica. (2007) 24 (4): 356‒362.
15. Rastogi V, Yadav P, Lal N, Rastogi P, Singh BK, Verma N, Verma A. Mathematical prediction of pharmacokinetic parameters-an in-vitro approach for investigating pharmaceutical products for IVIVC. Future J. Pharm. Sci. (2018) 4 (2): 175‒184.
16. Ilango KB, Kavimani S. A systematic review of mathematical models of pharmaceutical dosage forms. Int. J. Curr. Pharm. Rev. Res. (2015) 6 (1): 59-70.
17. Ramteke KH, Dighe PA, Kharat AR, Patil SV. Mathematical models of drug dissolution: a review. Sch. Acad. J. Pharm. (2014) 3 (5): 388-396.
18. Rivera-Leyva JC, García-Flores M, Valladares-Méndez A, Orozco-Castellanos M, Martínez-Alfaro M. Comparative studies of the dissolution profiles of oral ibuprofen suspension and commercial tablets using Biopharmaceutical Classification System Criteria. Indian J. Pharm. Sci. (2012) 74 (4): 312‒318.
19. Sudhir M, Divya Ch, Lakshmi Prasanti N, Liakhat Ali Sk, Fridepaul Ch, Jyothi N. Formulation and characterization of oral suspension containing ibuprofen. Asian J. Pharm. Technol. Inn. (2016) 4 (21): 23‒32.
20. Xu J, Zhang L, Shao X. Application of bio-predictive dissolution tools for the development of solid oral dosage forms: current industrial experience. Drug Dev. Ind. Pharm. (2022) 48 (3): 79‒97.
21. Taha NF, Emara LH. Convolution- and deconvolution-based approaches for prediction of pharmacokinetic parameters of diltiazem extended-release products in flow-through cell dissolution tester. AAPS PharmSciTech. (2022) 23 (6): 202.
22. García MA, González PM, Aceituno A, Al-Gousous J. Novel analytical solutions for convolution in compartmental pharmacokinetic models and application to non-bioequivalent formulations. Eur. J. Pharm. Sci. (2024) 202: 106892.
23. Sánchez-Dengra B, González-García I, González-Álvarez M, González-Álvarez I, Bermejo M. Two-step in vitro-in-vivo correlations: deconvolution and convolution methods, which one gives the best predictability? Comparison with one-step approach. Eur. J. Pharmaceut. Biopharmaceut. (2021) 158: 185‒197.
24. Arcaro R, Rereira da Veiga CR, Vieira da Silva W, Pereira da Veiga C. Attitude and purchase intention to generic drugs. Int. J. Environ. Res. Public Health (2021) 18: 4579.
25. Illamola SM, Birnbaum AK, Sherwin CM. Generic drug products in paediatrics: where are the data?. Br. J. Clin. Pharmacol. (2019) 85: 1871‒1873.
- Abstract Viewed: 91 times
- IJPS_Volume21_Issue1_Pages461-469 Downloaded: 64 times